CHEMM ChemoMetec

Upgrade of revenue and operating profit guidance

Upgrade of revenue and operating profit guidance

ANNOUNCEMENT NO. 279

16 October 2024



Upgrade of revenue and operating profit guidance

ChemoMetec sustained its positive performance in the first quarter of 2024/25 with better-than-expected sales and order intake.

Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 445-460 million range, up from DKK 435-450 million in the most recent guidance, and EBITDA in the DKK 222-230 million range, up from DKK 216-223 million previously. 

ChemoMetec’s interim report for Q1 2024/25 is scheduled to be released on Thursday, 7 November 2024.



Additional information

Martin Helbo Behrens, CEO

Tel.: (+45) 48 13 10 20

Kim Nicolajsen, CFO

Tel.: (+45) 48 13 10 20



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.

ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to .



EN
16/10/2024

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
CHEMM CHEMOMETEC

ChemoMetec (Buy, TP: DKK540.00) - More than on track

The Q1 results were much stronger than expected, even after the increased full-year guidance in October, which now already looks conservative to us. In our view, this looks like a ‘beat and raise’ strategy, and we would not be surprised to see several guidance increases as new products increasingly contribute and end-markets continue to improve, which, considering the operating leverage, could drive significant positive consensus earnings revisions. We reiterate our BUY and have raised our targe...

11/10/24 November 10, 2024 1 EN
Free Trial
CHEMM CHEMOMETEC

ChemoMetec A S: 2 directors

Two Directors at ChemoMetec A S bought 9,175 shares at between 456.010DKK and 459.980DKK. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

11/08/24 November 8, 2024 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 284 8. november 2024 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af næstformand for bestyrelsen Martin Glensbjergs transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFO Telefon: (+45) 48 13 10 20         ...

November 8, 2024 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 284 8 November 2024 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Vice Chair of ChemoMetec’s Board of Directors Martin Glensbjerg in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) ...

November 8, 2024 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 283 8. november 2024 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af administrerende direktør Martin Helbo Behrens’ transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFO Telefon: (+45) 48 13 10...

November 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch